Interim estimates of male human papillomavirus vaccination coverage in the school-based program in Australia
DOI:
https://doi.org/10.33321/cdi.2015.39.17Keywords:
HPV vaccine, school based vaccinationAbstract
In February 2013, following the successful establishment of the National Human Papillomavirus (HPV) Vaccination Program for females in Australia in 2007, the program was extended to males. This followed a recommendation by the Pharmaceutical Benefits Advisory Committee that extension of the quadrivalent HPV vaccine program to males would be acceptably cost-effective compared with female only vaccination, and subsequent listing on the National Immunisation Program of quadrivalent HPV vaccine for males. In this report we present interim estimates of male HPV vaccination coverage achieved in the school-based program in 2013.
Downloads
References
Brotherton JML, Murray SL, Hall MA, Andrewartha LK, Banks CA, Meijer D, Pitcher HC, Scully MM, Molchanoff L. Human papillomavirus vaccine coverage among female Australian adolescents: success of the school-based approach. Med J Aust 2013;199(9):614–617.
Brotherton JML, Liu B, Donovan B, Kaldor JM, Saville M. Human papillomavirus (HPV) vaccination coverage in young Australian women is higher than previously estimated: independent estimates from a nationally representative mobile phone survey. Vaccine 2014;32(5):592– 597.
Pharmaceutical Benefits Advisory Committee. Public Summary Document. Quadrivalent human papillomavirus (Types 6, 11, 16, 18) recombinant vaccine, solution for injection, 0.5 mL, solution for injection pre-filled syringe single dose, Gardasil® – November 2011. Accessed 14 July 2014. Available from: www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2011-11/pbac-psd-quadrivalent-nov11
Ward K, Quinn H, Bachelor M, Bryant V, Campbell-Lloyd S, Newbound A, et al. Adolescent school-based vaccination in Australia. Commun Dis Intell 2013;37(2):E156–E167.
Gertig DM, Brotherton JM, Saville M. Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia. Sex Health 2011;8(2):171–178.
Brotherton JM, Batchelor M, Winch K. Utility of reports and routine correspondence from the National HPV Vaccination Program Register. [letter] Med J Aust 2013;199(7):463.
Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Cummins E, Liu B, et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012;206(11):1645–1651.
Ali H, Donovan B, Wand H, Read TR, Regan DG, Grulich AE, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 2013;346:f2032.
Gertig DM, Brotherton JML, Budd AC, Drennan K, Chappell G, Saville AM. Impact of a population –based HPV vaccination program on cervical abnormalities: A data linkage study. BMC Med 2013;11:227.
Downloads
Published
How to Cite
License
Copyright (c) 2015 Communicable Diseases Intelligence

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
